S R Steinhubl

Summary

Affiliation: Wilford Hall Medical Center
Country: USA

Publications

  1. ncbi request reprint Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA
    Circulation 103:1403-9. 2001
  2. ncbi request reprint Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, San Antonio, Texas, USA
    Circulation 103:2572-8. 2001
  3. ncbi request reprint Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA
    Circulation 100:1977-82. 1999
  4. ncbi request reprint Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Tex 78236 5300, USA
    JAMA 281:806-10. 1999
  5. ncbi request reprint Complications of oral antiplatelet medications
    E Van De Graaff
    Department of Cardiology, Wilford Hall Medical Center, 2200 Bergquist Drive, Suite 1, Lackland AFB, TX 78236, USA
    Curr Cardiol Rep 3:371-9. 2001
  6. ncbi request reprint Variability in response to aspirin: do we understand the clinical relevance?
    C L Campbell
    Division of Cardiology, Wilford Hall Medical Center and San Antonio Uniform Health Sciences Consortium, San Antonio, TX, USA
    J Thromb Haemost 3:665-9. 2005
  7. pmc Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment
    D Mukherjee
    Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, Kentucky 40536 0200, USA
    Heart 92:49-51. 2006

Detail Information

Publications7

  1. ncbi request reprint Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA
    Circulation 103:1403-9. 2001
    ..The role of enhanced antiplatelet protection through pretreatment with the platelet ADP-receptor antagonist ticlopidine in preventing both the early and late complications of coronary stenting has not previously been explored...
  2. ncbi request reprint Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, San Antonio, Texas, USA
    Circulation 103:2572-8. 2001
    ..The optimal level of platelet inhibition with a glycoprotein (GP) IIb/IIIa antagonist necessary to minimize thrombotic complications in patients undergoing a percutaneous coronary intervention (PCI) is currently unknown...
  3. ncbi request reprint Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland AFB, TX 78236, USA
    Circulation 100:1977-82. 1999
    ..Diabetic patients in particular are a subgroup of patients with known underlying platelet abnormalities whose long-term response to abciximab has been shown to vary from that of nondiabetic patients...
  4. ncbi request reprint Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
    S R Steinhubl
    Department of Cardiology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Tex 78236 5300, USA
    JAMA 281:806-10. 1999
    ....
  5. ncbi request reprint Complications of oral antiplatelet medications
    E Van De Graaff
    Department of Cardiology, Wilford Hall Medical Center, 2200 Bergquist Drive, Suite 1, Lackland AFB, TX 78236, USA
    Curr Cardiol Rep 3:371-9. 2001
    ..This review summarizes the adverse profiles of each of these drug classes and draws on data gathered in large clinical studies...
  6. ncbi request reprint Variability in response to aspirin: do we understand the clinical relevance?
    C L Campbell
    Division of Cardiology, Wilford Hall Medical Center and San Antonio Uniform Health Sciences Consortium, San Antonio, TX, USA
    J Thromb Haemost 3:665-9. 2005
    ..In this review we discuss the clinical data regarding this phenomenon and the need for prospective evaluation of aspirin non-responders...
  7. pmc Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment
    D Mukherjee
    Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, Kentucky 40536 0200, USA
    Heart 92:49-51. 2006
    ..To assess the effectiveness of long term treatment with clopidogrel of patients with extracardiac vascular disease (ECVD) (a history of either peripheral arterial disease or cerebrovascular disease)...